Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Patients with primary biliary cholangitis (PBC) often suffer with pruritus. We describe the impact of pruritus on quality of life and how it is managed in a real-world cohort. METHODS: TARGET-PBC is a longitudinal observational cohort of patients with PBC across the USA. Data include information from medical records for three years prior to the date of consent up to 5 years of follow-up. Enrolled patients were asked to complete patient-reported outcome surveys: PBC-40, 5-D itch, and the PROMIS fatigue survey. Kruskal-Wallis tests were used to compare differences in symptoms between groups. RESULTS: A total of 211 patients with completed PRO surveys were included in the current study. PRO respondents were compared with non-respondents in the TARGET-PBC population and were broadly similar. Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue. Patients reporting clinically significant pruritus were more likely to receive treatment, but 33% had never received treatment (no itch = 43.9%, mild itch = 38.3%). CONCLUSIONS: The prevalence of pruritus was high in this population, and those reporting clinically significant pruritus had a higher likelihood of having advanced disease and worse quality of life. However, this study found that pruritus in PBC is under-treated. This may be due in part to ineffectiveness of current treatments, poor tolerance, or the lack of FDA-approved medications for pruritus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Recent large clinical trials have found a baseline prevalence of pruritus in patients with PBC of about 50–70% [1, 2].”
BackgroundSelf-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 5×
“1 3 approach to treat pruritus in PBC,[5, 6], but the extent of uptake of these recommendations in the medical community is also unknown.”
InfluentialSelf-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362 · cited 1×
“Ethnic diversity, while still limited, was increased compared to other PBC studies [17].”
Resultde Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Reig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.287 · Cited by 115
Research works printed but not linked: 9
- Jones DE et al. An integrated care pathway improves quality of life in primary biliary cirrhosis. QJM: Int J Med 2008;101:535–543. · DOI · Paper page
- Hegade VS et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. Clin Gastroenterol Hepatol 2019;17:1379–1387. · DOI · Paper page
- Levy C et al. A real-world observational cohort of patients with primary biliary cholangitis: target-primary biliary cholangitis study design and rationale. Hepatol Commun 2018;2:484–491. · DOI
- Jacoby A et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 2005;54:1622–1629. · DOI · Paper page
- Elman S et al. The 5-D itch scale: a new measure of pruritus. British J Dermatol 2010;162:587–593. · DOI · Paper page
- Al-Harthy N et al. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology 2010;52:562–570. · DOI · Paper page
- Hegade VS et al. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Front Gastroenterol 2016;7:158–166. · DOI · Paper page
- Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol: JDD 2010;9:992–997.
- Daikeler J, Bošnjak M, Lozar Manfred K. Web versus other survey modes: an updated and extended meta-analysis comparing response rates. J Surv Stat Methodol 2020;8:513–539. · DOI · Paper page
Cited by
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2306185 · Cited by 314
Self-citationTanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
Self-citationHirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00192-x · Cited by 34
Self-citationAdvancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“Pruritus occurs in up to 80% of PBC patients and can significantly impair their quality of life [100,101].”
Metadata
- Authors
- Mayo, M. J., Carey, E., Smith, H. T., Mospan, A. R., McLaughlin, M., Thompson, A., Morris, H. L., Sandefur, R., Kim, W. R., Bowlus, C., the TARGET-PBC Investigators, Ankoma-Sey, V., Bernstein, D., Borg, B., Bowlus, C., Brown, R., Carey, E., Clark, V., Darling, J., Dranoff, J., Elbeshbeshy, H., Forman, L., Goel, A., Hanje, J., Harrison, S., Janardhan, S., Jesudoss, R., Kim, D., King, L., Landis, C., Levy, C., Lok, A., Lucey, M., Luketic, V., Manch, R., Mark, W., Mayo, M., Mena, E., Modi, A., Reddy, G., Reddy, K. R., Rochling, F., Rojter, S., Rubin, R., Russo, M., Shiffman, M., Silveira, M., Stanca, C., Thuluvath, P., Verna, E., Weiss, L. M., & Levy, C.
- Venue
- Digestive Diseases and Sciences
- Published
- 2022-06-15
- Volume
- 68
- Issue
- 3
- Pages
- 995-1005
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W4282926324
- Cited by
- 78
- References
- 7
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-08-09)
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Funders
- GlaxoSmithKline (213259)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. https://app.cochat.ai/papers/10.1007/s10620-022-07581-x
- The paper
- Mayo, M. J., Carey, E., Smith, H. T., Mospan, A. R., McLaughlin, M., Thompson, A., Morris, H. L., Sandefur, R., Kim, W. R., Bowlus, C., the TARGET-PBC Investigators, Ankoma-Sey, V., Bernstein, D., Borg, B., Bowlus, C., Brown, R., Carey, E., Clark, V., Darling, J., . . . Levy, C. (2023). Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-022-07581-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.